Peer-influenced content. Sources you trust. No registration required. This is HCN.

Northwestern MedicineA combination of BET inhibitor with anti-PD-1 shows promise in murine model

When tested in mice with pancreatic cancer, a BET inhibitor/anti-PD-1 combination prevented neoplastic transformation induced by the oncogene KRAS, increased survival and increased the recruitment of cytotoxic T-cells to the tumor.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form